Clinical Trial Detail

NCT ID NCT01950390
Title Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot be Removed by Surgery
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

melanoma

Therapies

Ipilimumab

Bevacizumab + Ipilimumab

Age Groups: senior adult

No variant requirements are available.